30 окт. 2024 г. · Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

BRISTOL-MYERS SQUIBB Development Pipeline · Development · ONCOLOGY · IMMUNOSCIENCE · CARDIOVASCULAR · FIBROTIC DISEASES · GENETICALLY DEFINED DISEASES. Phase I.

15 нояб. 2024 г. · The pipeline at Bristol Myers Squibb encompasses differentiated research platforms across hematology, oncology, immunology, cardiovascular disease and ...

25 апр. 2024 г. · The company has discontinued 12 programs, including a successor version of its immunotherapy Yervoy, and will continue to review its pipeline ...

In Our Pipeline · Cardiovascular · Fibrotic Disease · Hematology. Immunology; Neuroscience; Solid Tumors.

6 сент. 2023 г. · An overview of the distribution of therapeutic areas. The organization has a strong focus on Neoplasms, with 212 drugs developed in this area.

26 апр. 2024 г. · Overall, Bristol Myers removed eight programs from Phase 1 development and six from Phase 2, according to an Endpoints News review of its fourth ...

14 сент. 2023 г. · The drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies ...

15 сент. 2023 г. · Bristol Myers Squibb could clinch more than 25 label expansions for its approved drugs over the coming years, the company said.

295,00 $ Pipeline Drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre- ...